1. Blanchard P, Baujat B, Holostenco V et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumor site. Radiother Oncol, 2011;100:33–40.
2. Burtness B, Harrington KJ, Greil R et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet, 2019 Nov 23;394(10212): 1915–1928.
3. Cohen EEW, Soulières D, Le Tourneau C et al. KEYNOTE-040 investigators. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet, 2019 Jan 12;393(10167): 156–167.
4. Debaere D, Vander Porten V, Nuyts S et al. Cyclophosphamide, doxorubicin and cisplatin in advanced salivary gland cancer. B-ENt, 2011;7: 1–6.
5. Drilon A, Laetsch TW, Kummar S et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med, 2018 Feb 22;378(8): 731–739.